Avinger (NASDAQ:AVGR) and Perspective Therapeutics (NYSE:CATX) Head to Head Review

Avinger (NASDAQ:AVGR) and Perspective Therapeutics (NYSE:CATX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

Risk and Volatility

Avinger has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500. Comparatively, Perspective Therapeutics has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500.

Earnings & Valuation

This table compares Avinger and Perspective Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avinger	$7.26 million	0.22	-$18.32 million	($11.06)	-0.04
Perspective Therapeutics	$1.43 million	124.06	-$46.51 million	N/A	N/A

Avinger has higher revenue and earnings than Perspective Therapeutics.

Profitability

This table compares Avinger and Perspective Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Avinger	-261.06%	-5,527.11%	-123.25%
Perspective Therapeutics	-4,096.66%	-27.40%	-23.16%

Institutional and Insider Ownership

18.3% of Avinger shares are held by institutional investors. Comparatively, 54.7% of Perspective Therapeutics shares are held by institutional investors. 42.8% of Avinger shares are held by insiders. Comparatively, 3.7% of Perspective Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Avinger and Perspective Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avinger	0	0	0	0	0.00
Perspective Therapeutics	0	1	7	3	3.18

Perspective Therapeutics has a consensus target price of $12.50, indicating a potential upside of 423.01%. Given Perspective Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Perspective Therapeutics is more favorable than Avinger.

Summary

Perspective Therapeutics beats Avinger on 9 of the 13 factors compared between the two stocks.

About Avinger

Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. Its lumivascular products comprise Lightbox imaging consoles; the Ocelot and Tigereye family of devices, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. The company is also developing IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. The company was incorporated in 2007 and is based in Redwood City, California.

About Perspective Therapeutics

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.